AU2021203261B1 - Novel dioxoloisoquinolinone derivatives and use thereof - Google Patents

Novel dioxoloisoquinolinone derivatives and use thereof Download PDF

Info

Publication number
AU2021203261B1
AU2021203261B1 AU2021203261A AU2021203261A AU2021203261B1 AU 2021203261 B1 AU2021203261 B1 AU 2021203261B1 AU 2021203261 A AU2021203261 A AU 2021203261A AU 2021203261 A AU2021203261 A AU 2021203261A AU 2021203261 B1 AU2021203261 B1 AU 2021203261B1
Authority
AU
Australia
Prior art keywords
dimethyl
methyl
oxo
dioxolo
dihydropyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021203261A
Other languages
English (en)
Inventor
Young Gil Ahn
Dong Jin Hong
Ji Young Hwang
Seung Hyun Jung
Seo Hee Kim
Shin Mee Mah
So Min Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200102034A external-priority patent/KR102386403B1/ko
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of AU2021203261B1 publication Critical patent/AU2021203261B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2021203261A 2020-08-13 2021-05-20 Novel dioxoloisoquinolinone derivatives and use thereof Active AU2021203261B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2020-0102034 2020-08-13
KR1020200102034A KR102386403B1 (ko) 2020-08-13 2020-08-13 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
PCT/KR2021/095037 WO2022035303A1 (en) 2020-08-13 2021-05-20 Novel dioxoloisoquinolinone derivatives and use thereof

Publications (1)

Publication Number Publication Date
AU2021203261B1 true AU2021203261B1 (en) 2021-09-23

Family

ID=77746355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021203261A Active AU2021203261B1 (en) 2020-08-13 2021-05-20 Novel dioxoloisoquinolinone derivatives and use thereof

Country Status (11)

Country Link
US (1) US11535629B2 (es)
EP (1) EP4196483A1 (es)
JP (2) JP7387907B2 (es)
CN (1) CN116194108A (es)
AU (1) AU2021203261B1 (es)
BR (1) BR112023002077A2 (es)
CA (1) CA3165787C (es)
IL (1) IL300577A (es)
MX (1) MX2023001603A (es)
PE (1) PE20230732A1 (es)
ZA (1) ZA202301143B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200101219A (ko) * 2019-02-19 2020-08-27 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019226491A1 (en) * 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2020171606A1 (ko) * 2019-02-19 2020-08-27 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
ES2774900T3 (es) * 2014-03-17 2020-07-23 Daiichi Sankyo Co Ltd Derivados de 1,3-benzodioxol como inhibidores de EZH1 y/o EZH2
MD4820C1 (ro) * 2014-06-17 2023-03-31 Pfizer Inc. Compuşi dihidroizochinolinonici substituiţi
WO2015193768A1 (en) * 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
WO2018081530A1 (en) * 2016-10-28 2018-05-03 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating ezh2-mediated cancer
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
CN109516961B (zh) * 2018-12-25 2021-01-01 浙江大学 氨基喹唑啉酮和氨基异喹啉酮衍生物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019226491A1 (en) * 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2020171606A1 (ko) * 2019-02-19 2020-08-27 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도

Also Published As

Publication number Publication date
CN116194108A (zh) 2023-05-30
CA3165787C (en) 2023-06-06
CA3165787A1 (en) 2022-02-17
JP2023155432A (ja) 2023-10-20
MX2023001603A (es) 2023-03-07
JP7387907B2 (ja) 2023-11-28
ZA202301143B (en) 2024-05-30
EP4196483A1 (en) 2023-06-21
US20220275000A1 (en) 2022-09-01
IL300577A (en) 2023-04-01
PE20230732A1 (es) 2023-05-03
JP2023517272A (ja) 2023-04-25
BR112023002077A2 (pt) 2023-02-28
US11535629B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
JP6494622B2 (ja) カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体
EP3517112B1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
EP3381896B1 (en) Biphenyl compound or salt thereof
KR102302830B1 (ko) 1,3-벤조디옥솔 유도체
CN107428758B (zh) 丙烯酸类衍生物、其制备方法及其在医药上的用途
CN110872289A (zh) 作为IDO1和/或TDO抑制剂的新颖的8-取代的咪唑并[1,5-a]吡啶
EP3632897A1 (en) Novel biphenyl compound or salt thereof
CN109415361B (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
EP3862348A1 (en) Isoindoline compound, preparation method, pharmaceutical composition and use thereof
TW202045512A (zh) 新型雜環三環衍生物化合物及其用途
KR102386403B1 (ko) 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
CN106928219A (zh) 含氮稠杂环化合物、制备方法、中间体、组合物和应用
EP3173413A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
EP3633380A1 (en) Method for predicting therapeutic effect of lsd1 inhibitor based on expression of insm1
CN110156656A (zh) 五元杂芳环衍生物、其制备方法、药物组合物及应用
CN111989332B (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
CN104557913B (zh) 吡啶并嘧啶类化合物,其制备方法和用途
AU2021203261B1 (en) Novel dioxoloisoquinolinone derivatives and use thereof
CN110407854B (zh) 新的四环化合物
US10654868B2 (en) Dihydropyrazole azepine compound serving as Akt inhibitor
EP4055013B1 (en) Wdr5 inhibitors and modulators
CN115724830A (zh) 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
CN115785088A (zh) 作为sos1抑制剂的化合物及其应用
WO2021088992A1 (zh) 作为prmt5抑制剂的四氢异喹啉螺环化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)